| Literature DB >> 34943187 |
Yining Lu1, Huw D Wiltshire1, Julien S Baker2, Qiaojun Wang3.
Abstract
Participation in exercise promotes health. High intensity exercise (HIE) has become increasingly popular among the general population, however, its effects on exercise-induced oxidative stress and antioxidant status in untrained humans is not clear. The aim of this systematic review was to investigate the influence of HIE on oxidative stress and antioxidant status in untrained humans. Web of Science, PubMed, MEDLINE, and Scopus were searched until March 2021. A methodological quality assessment valuation/estimation was additionally carried out in the final sample of studies. Following the PRISMA selection process, 21 studies were finally included. There was strong evidence that acute oxidative stress following the cessation of HIE exists when compared to resting states. The HIE-induced oxidative stress is transient and is most likely restored to normal levels within 24 h due to the stimulated endogenous antioxidant system whose response was lagging and lasting. Physically active humans had better antioxidant systems and suffered less oxidative stress after HIE. A physically active lifestyle was considered to enhance antioxidant capacity. For untrained humans, HIE with intensities above 70% VO2max are proposed for initial exercise levels based on the findings reported here.Entities:
Keywords: antioxidant; high intensity exercise; oxidative stress; untrained
Year: 2021 PMID: 34943187 PMCID: PMC8698973 DOI: 10.3390/biology10121272
Source DB: PubMed Journal: Biology (Basel) ISSN: 2079-7737
Figure 1PRISMA flow diagram displaying the selection process.
Methodological quality assessment.
| Reference | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ammar et al., 2020 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 80% |
| Baker et al., 2004 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 80% |
| Berzosa er al., 2011 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 80% |
| Bogdanis et al., 2013 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 60% |
| Bouzid et al., 2014 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 70% |
| Djordjevic et al., 2012 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 70% |
| Falone et al., 2010 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 70% |
| Finkler et al., 2016 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 60% |
| Fisher et al., 2011 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 60% |
| Groussard et al., 2003 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 60% |
| Hajizadeh et al., 2017 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 80% |
| Jammes et al., 2004 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 60% |
| Jamurtas et al., 2018 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 80% |
| Kyparos et al., 2007 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 70% |
| Miyazaki et al., 2001 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 70% |
| Parker et al., 2014 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 60% |
| Parker et al., 2018 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 80% |
| Seifi-Skishahr et al., 2008 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 60% |
| Steinberg et al., 2007 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 60% |
| Wadley et al., 2016 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 80% |
| Wiecek et al., 2018 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 60% |
| Reporting | Internal validity—bias | Internal validity—confounding | Power | Average | |||||||
| TOTAL/21 | 21 | 21 | 21 | 21 | 0 | 0 | 21 | 11 | 8 | 21 | 69% |
Details of exercise testing and training of the included studies.
| Reference | Exercise Testing | Training | ||||||
|---|---|---|---|---|---|---|---|---|
| Modality | Type of Protocol | No. of Bouts | Duration of Bouts | Duration of Protocol | W/R | Intensity (W/R) | Duration, Frequency, (No. of Bouts) × (Duration of Bout/Intensity)/Duration of Recovery | |
| Ammar et al., 2020 [ | Cycling | Maximal | 1 | 30 s | 30 s | All-out | ||
| Ammar et al., 2020 [ | Cycling | Combined (maximal and moderate intensity continuous) | 1 | 30 s + 30 min | 30 s + 30 min | All-out + 60% MAP | ||
| Baker et al., 2004 [ | Cycling | Maximal | 1 | 30 s | 30 s | All-out | ||
| Baker et al., 2004 [ | Cycling | Maximal | 1 | 30 s | 30 s | All-out | ||
| Berzosa er al., 2011 [ | Cycling | Incremental | 1 | Incremental intensity to exhaustion | ||||
| Berzosa er al., 2011 [ | Cycling | Maximal | 1 | 100% VO2max to exhaustion | ||||
| Berzosa er al., 2011 [ | Cycling | High-intensity continuous | 1 | 30 min | 30 min | 70% VO2max | ||
| Bogdanis et al., 2013 [ | Cycling | Sprint interval | 4 | 30 s | 14 min | 1/8 | All-out/Active recovery | 3 weeks, 3 sessions/week, (4–6) × (30 s/all-out)/4 min |
| Bogdanis et al., 2013 [ | Cycling | Sprint interval | 4 | 30 s | 14 min | 1/8 | All-out/Active recovery | |
| Bouzid et al., 2014 [ | Treadmill | Incremental | 1 | Incremental intensity to exhaustion | ||||
| Bouzid et al., 2014 [ | Treadmill | Incremental | 1 | Incremental intensity to exhaustion | ||||
| Djordjevic et al., 2012 [ | Cycling | Incremental | 1 | Incremental intensity to exhaustion | ||||
| Djordjevic et al., 2012 [ | Cycling | Incremental | 1 | Incremental intensity to exhaustion | ||||
| Falone et al., 2010 [ | Treadmill | Incremental | 1 | Incremental intensity to exhaustion | ||||
| Falone et al., 2010 [ | Treadmill | Incremental | 1 | Incremental intensity to exhaustion | ||||
| Finkler et al., 2016 [ | Cycling | Incremental | 1 | Incremental intensity to exhaustion | ||||
| Fisher et al., 2011 [ | Cycling | High-intensity interval | 4 | 30 s | 14 min | 1/8 | 90% Max-AP/15% Max-AP | |
| Fisher et al., 2011 [ | Cycling | High-intensity interval | 4 | 30 s | 14 min | 1/8 | 90% Max-AP/15% Max-AP | |
| Fisher et al., 2011 [ | Cycling | High-intensity interval | 4 | 30 s | 14 min | 1/8 | 90% Max-AP/15% Max-AP | |
| Groussard et al., 2003 [ | Cycling | Maximal | 1 | 30 s | 30 s | All-out | ||
| Hajizadeh et al., 2017 [ | Treadmill | High-intensity continuous | 4 | 10 min | 49 min | 10/3 | 70–75% VO2max/50–60% VO2max for the first 12 weeks; 75–85% VO2max/50–60% VO2max for the final 12 weeks | 24 weeks, 3 sessions/week, 4 × [10 min/(70–75%) − (75–85%)VO2max]/3 min |
| Hajizadeh et al., 2017 [ | Treadmill | High-intensity interval | 10 | 1 min | 19 min | 1/1 | 75–85% VO2max/45–50% VO2max for the first 12 weeks; 85–95% VO2max/45–50% VO2max for the final 12 weeks | 24 weeks, 3 sessions/week, 10 × [1 min/(75–85%) − (85–95%)VO2max]/1 min |
| Jammes et al., 2004 [ | Cycling | Incremental | 1 | Incremental intensity to VO2max | ||||
| Jamurtas et al., 2018 [ | Cycling | Sprint interval | 4 | 30 s | 14 min | 1/8 | All-out | |
| Jamurtas et al., 2018 [ | Cycling | High-intensity continuous | 1 | 30 min | 30 min | 70% VO2max | ||
| Kyparos et al., 2007 [ | Shuttle run | Maximal | 1 | All-out | ||||
| Miyazaki et al., 2001 [ | Cycling | Incremental | 1 | Incremental intensity to exhaustion | 12 weeks, 5 sessions/week, 1 × (60 min/80% VO2max) | |||
| Miyazaki et al., 2001 [ | Cycling | Incremental | 1 | Incremental intensity to exhaustion | ||||
| Parker et al., 2014 [ | Cycling | High-intensity interval | 1 | 5 min | 5 min | 5/12 | 70% VO2max/passive seated rest | |
| Parker et al., 2014 [ | Cycling | High-intensity interval | 1 | 5 min | 5 min | 5/12 | 85% VO2max/passive seated rest | |
| Parker et al., 2014 [ | Cycling | High-intensity interval | 1 | 5 min | 5 min | 5/12 | 100% VO2max/passive seated rest | |
| Parker et al., 2018 [ | Cycling | High-intensity interval | 5 | 4 min | 24 min | 4/1 | 75%Wmax | |
| Parker et al., 2018 [ | Cycling | Sprint interval | 4 | 30 s | 15.5 min | 1/9 | All-out | |
| Seifi-Skishahr et al., 2008 [ | Treadmill | High-intensity continuous | 1 | 30 min | 30 min | 75% VO2max | ||
| Steinberg et al., 2007 [ | Cycling | Incremental | 1 | Incremental intensity to exhaustion | ||||
| Wadley et al., 2016 [ | Cycling | High-intensity interval | 10 | 1 min | 19 min | 1/1 | 90% VO2max | |
| Wadley et al., 2016 [ | Cycling | High-intensity continuous | 1 | 20 min | 20 min | 80% VO2max | ||
| Wiecek et al., 2018 [ | Cycling | Maximal | 1 | 20 s | 20 s | All-out | ||
Note: FFM, fat-free mass; HICE, high-intensity continuous exercise; HIIE, high-intensity interval exercise; LV-HIIE, low-volume high-intensity interval exercise; Max-AP, maximum anaerobic power; SIE, sprint interval exercise; VO2max, maximal oxygen uptake; All-out: encompasses intensities described by the authors as “sprints”, “maximal”, “maximal exercise”, “exhaustion”, “near the VO2max”.
Individual time-points (TP) of measures of oxidative stress and relevant findings for each study.
| Reference | TP0 (0 min) | TP1 (5 min) | TP2 (10 min) | TP3 (20 min) | TP4 (30 min) | TP5 (1 h) | TP6 (2 h) | TP7 (3 h) | TP8 (24 h) | TP9 (48 h) | TP10 (72 h) | Findings |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ammar et al., 2020 [ | 0 min | 5 min | 10 min | 20 min | MDA↑ at TP0 in AnEx; MDA↑ at TP2 in CombEx. MDA continued to increase at TP3 in both Ex; GPX, SOD↑ at TP0 in both Ex; AnEx resulted in greater SOD and GPX at TP0 and TP1. SOD peaked at TP0 in the AnEx; GPX peaked was at TP3 in the CombEx; TAC did not change until TP3 in both Ex. | |||||||
| Baker et al., 2004 [ | 0 min | 24 h | MDA↑ at TP0 in the TBM protocol; MDA returned to baseline values at TP8. | |||||||||
| Berzosa er al., 2011 [ | 0 min | GPX, CAT and TAC↑ at TP0 in all three Ex; SOD↑ at TP0 in all-out and high intensity continuous Ex. | ||||||||||
| Bogdanis et al., 2013 [ | 30 min | 24 h | 48 h | TBARS↑ at TP4 and peaked at TP8 in both pre and post training; Post training resulted in lower TRARS at all TPs. GPX↑ and peaked at TP8 in both pre and post training; CAT↑ and peaked at TP4 in both pre and post training; TAC↑ at TP4 and peaked at TP8 only in pre training. Post training resulted in higher GPX, CAT and TAC in all TPs. | ||||||||
| Bouzid et al., 2014 [ | 5 min (MDA) | 20 min (SOD, GPX) | MDA↑ at TP1 in old group; GPX and SOD↑ at TP3 in young group. | |||||||||
| Djordjevic et al., 2012 [ | 0 min | TBARS↓ at TP0 only in non-athletes; CAT↓ at TP0 only in athletes. GSH did not change in both groups. | ||||||||||
| Falone et al., 2010 [ | 0 min | MDA did not change at TP0 in both amateur runner and untrained group; TAC↓ at TP0 only in untrained group. | ||||||||||
| Finkler et al., 2016 [ | 5 min | 1 h | TBARS↑ at TP1 and returned to baseline values at TP5; CAT↑ at TP1 and continued to increase at TP5. GPX did not change until TP5. | |||||||||
| Fisher et al., 2011 [ | 0 min | 3 h | 24 h | TBARS↑ at TP0 in the first and second test and at TP7 in the second test; CAT↑ at TP0 in the first and second test; SOD↑ at TP0 and TP7 in all three tests, and returned to baseline value at TP8; GPX↑ at TP0 in the first and third test, and returned to baseline value at TP7. | ||||||||
| Groussard et al., 2003 [ | 0 min | 5 min | 10 min | 20 min | 40 min | MDA and TBARS↓ at TP3 and TP5; SOD↓ at TP0; GPX did not change until TP5. | ||||||
| Hajizadeh et al., 2017 [ | 24 h | SOD and CAT↑ at TP8 in both HICT and group after 24 weeks’ training; MDA and TAC↑ at TP8 only in HIIE group after 24 weeks’ training. | ||||||||||
| Jammes et al., 2004 [ | 0 min | 5 min | 10 min | 20 min | 30 min | TBARS↑ at TP1 and remained increased until TP4; GSH↓ at TP1 and returned to baseline at TP2. | ||||||
| Jamurtas et al., 2018 [ | 0 min | 24 h | 48 h | 72 h | TBARS and CAT did not change until TP10 in both HIIE and HICE; TAC↑ at TP0 in HICE, and ↑ at TP0 and TP8 in HIIE. | |||||||
| Kyparos et al., 2007 [ | 0 min | TBARS, CAT and TAC↑ at TP0; GSH↓ at TP0. | ||||||||||
| Miyazaki et al., 2001 [ | 0 min | TBARS↑ at TP0 in both pre- and post-training; Post training resulted in lower TBARS at TP0; SOD, GPX and CAT did not change at TP0. | ||||||||||
| Parker et al., 2014 [ | 0 min | OS did not change in all three tests; TAC↑ at TP0 in all three test; 100% VO2max test resulted in the highest TAC at TP0. | ||||||||||
| Parker et al., 2018 [ | 0 min | 1 h | 2 h | 3 h | TBARS and SOD↓ at TP0, TP5 and TP6 in both HIIE and SIE; CAT did not change until TP7 in both HIIE and SIE. | |||||||
| Seifi-Skishahr et al., 2008 [ | 0 min | 2 h | 24 h | MDA↑ at TP6. | ||||||||
| Steinberg et al., 2007 [ | 0 min | 5 min | 10 min | 20 min | 30 min | TBARS↑ at TP1 and TP2; GSH↓ at TP2 and TP3. | ||||||
| Wadley et al., 2016 [ | 0 min | 30 min | TAC↑ at TP4 relative to TP0 in both LV-HIIE and HICE. | |||||||||
| Wiecek et al., 2018 [ | 3 min | 15 min | 30 min | 1 h | 24 h | SOD↓ at TP3 relative to TP1; SOD↑ at TP4 and returned to baseline value at TP8; CAT↓ at TP3 relative to TP1; CAT↓ at TP5 and returned to baseline value at TP8; GPX↓ at TP3 and ↑ at TP8. |
Note: AnEx, Anerobic exercise; CAT, catalase; CombEX, Combined exercise; Ex, exercise; GPX, glutathione peroxidase activity; GSH, glutathione; MDA, malondialdehyde; SOD, superoxide dismutase; TAC, total antioxidant capacity; TBARS, thiobarbituric acid reactive substance; TP, time-point; ↑, significantly increase; ↓, significantly decrease.
Sociodemographic characteristics of participants.
| Reference | Age | Gender | Weight | BMI | VO2max | Diet | Lifestyle | Socio-Economic Level | Tobacco | Alcohol |
|---|---|---|---|---|---|---|---|---|---|---|
| Ammar et al., 2020 [ | 19.5 ± 1.7 | male | 71.8 ± 2.1 | - | - | no medications and antioxidant dietary supplement | physically inactive | - | - | - |
| Baker et al., 2004 [ | 23 ± 2 | male | 75.3 ± 11 | - | - | no medications and antioxidant dietary supplement | physically active | university student | - | - |
| Berzosa et al., 2011 [ | 23 ± 0.41 | male | 75.25 ± 2.84 | 23.72 ± 0.69 | 43.8 ± 1.58 | no medications and antioxidant dietary supplement | physically active | - | - | - |
| Bogdanis et al., 2013 [ | 24.3 ± 1.4 | male | 77.9 ± 2.9 | - | - | no medications and antioxidant dietary supplement | physically active | - | - | - |
| Bouzid et al., 2014 (young) [ | 20.3 ± 2.8 | 9 males/6 females | 66.1 ± 11.7 | - | 44.2 ± 5.2 | - | sedentary | - | - | - |
| Bouzid et al., 2014 (old) [ | 65.1 ± 3.57 | 7 males/8 females | 71.8 ± 7.6 | 23.2 ± 4.4 | - | - | sedentary | - | - | - |
| Djordjevic et al., 2012 (athletes) [ | 17.3 ± 0.2 | male | 80.9 ± 1.4 | 23.9 ± 0.3 | 44.6 ± 0.9 | no medications and antioxidant dietary supplement | regular training | - | non-smoking | no alcohol 48 h before test |
| Djordjevic et al., 2012 (non-athletes) [ | 17.3 ± 0.3 | male | 81.6 ± 6.1 | 23.6 ± 1.3 | 39.7 ± 1.3 | no medications and antioxidant dietary supplement | no regular physical activity | - | non-smoking | no alcohol 48 h before test |
| Falone et al., 2010 (amateur runner) [ | 42 ± 1 | male | - | 23.5 ± 0.5 | 48.5 ± 0.9 | no medications and antioxidant dietary supplement | regular training | - | - | no alcohol |
| Falone et al., 2010 (untrained) [ | 39 ± 3 | male | - | 26.1 ± 1.1 | 33.3 ± 1.2 | no medications and antioxidant dietary supplement | sedentary | no manual labor | - | no alcohol |
| Finkler et al., 2016 [ | 26.8 | male | 77.9 | 23.4 | 48.9 | no medications and antioxidant dietary supplement | physically active | - | non-smoking | - |
| Fisher et al., 2011 [ | 22 ± 2 | male | 83 ± 13.6 | - | 44.6 ± 8.2 | no medications and antioxidant dietary supplement | no regular physical activity | - | - | - |
| Groussard et al., 2003 [ | 22.2 ± 0.6 | male | 73.4 ± 2.2 | - | - | no medications and antioxidant dietary supplement | physically activity | university student | no tobacco in the last 6 months | no alcohol in the last 1 week |
| Hajizadeh et al., 2017 (HICE) [ | 32.3 ± 7.3 | male | 81.9 ± 7.2 | 26.8 ± 5.9 | 36 ± 4.6 | no medications and antioxidant dietary supplement | physically activity | - | no tobacco in the last 6 months | no alcohol in the last 6 months |
| Hajizadeh et al., 2017 (HIIE) [ | 30.4 ± 8.9 | male | 83.4 ± 6.3 | 27.6 ± 4.8 | 35.9 ± 4.7 | no medications and antioxidant dietary supplement | physically activity | - | no tobacco in the last 6 months | no alcohol in the last 6 months |
| Jammes et al., 2004 [ | 49 ± 3 | 14 males/5 females | 74 ± 3 | - | - | - | Sedentary | - | - | - |
| Jamurtas et al., 2018 [ | 22.4 ± 0.5 | male | 75.3 ± 8.9 | - | 45.3 ± 8.4 | no medications and antioxidant dietary supplement | - | - | non-smoking | no alcohol in the last 72 h |
| Kyparos et al., 2007 [ | 21.9 ± 0.9 | male | 73.9 ± 6.1 | - | - | - | - | college student | - | - |
| Miyazaki et al., 2001 (pre-training) [ | 19.4 ± 0.2 | male | 70.5 ± 2.6 | 23.4 ± 0.6 | 44.9 ± 1.5 | - | no regular physical activity | - | - | - |
| Miyazaki et al., 2001 (post-training) [ | 19.4 ± 0.2 | male | 70.4 ± 2.7 | 23.3 ± 0.7 | 49.7 ± 1.6 | - | no regular physical activity | - | - | - |
| Parker et al., 2014 [ | 22 ± 1 | male | 81.4 ± 2 | 25.4 ± 0.7 | 42.6 ± 2.1 | no medications and antioxidant dietary supplement | Sedentary | - | non-smoking | no alcohol in the last 24 h |
| Parker et al., 2018 [ | 25 ± 2 | 6 male/2 female | 79.4 ± 2.1 | 25 ± 1 | 48.4 ± 4 | no medications and antioxidant dietary supplement | physically activity | - | non-smoking | no alcohol in the last 24 h |
| Seifi-Skishahr et al., 2008 [ | 24.1 ± 3.1 | - | 71.9 ± 9.8 | - | 34.1 ± 2.7 | no medications and antioxidant dietary supplement | Sedentary | - | non-smoking | - |
| Steinberg et al., 2007 [ | 42 ± 4 | 9 males/6 females | 70 ± 3 | 22 ± 2 | 31.7 ± 2.5 | - | Sedentary | - | non-smoking | - |
| Wadley et al., 2016 [ | 22 ± 3 | male | - | 24 ± 3.1 | 42.7 ± 5 | no medications and antioxidant dietary supplement | - | - | non-smoking | no alcohol in the last 48 h |
| Wiecek et al., 2018 (female) [ | 22 ± 0.5 | female | 59.8 ± 2.1 | 21.5 ± 0.6 | - | no medications and antioxidant dietary supplement | physically activity | - | non-smoking | - |
| Wiecek et al., 2018 (male) [ | 21.6 ± 0.4 | male | 77.1 ± 2.7 | 23.7 ± 0.5 | - | no medications and antioxidant dietary supplement | physically activity | - | non-smoking | - |
Oxidative stress markers.
| Reference | Sample Size | Acute Response on Oxidative Stress and Antioxidant Status | |||||||
|---|---|---|---|---|---|---|---|---|---|
| MDA | TBARS | OS | TAC | CAT | SOD | GPX | GSH | ||
| Ammar et al., 2020 [ | 10 | sig ↑ | - | - | ns ↑ | - | sig ↑ * | sig ↑ * | - |
| Ammar et al., 2020 [ | 10 | ns ↑ | - | - | ns ↑ | - | sig ↑ * | sig ↑ * | - |
| Baker et al., 2004 [ | 18 | sig ↑ * | - | - | - | - | - | - | - |
| Baker et al., 2004 [ | 18 | ns ↑ * | - | - | - | - | - | - | - |
| Berzosa er al., 2011 [ | 34 | - | - | - | sig ↑ | sig ↑ | ns ↑ | sig ↑ | - |
| Berzosa er al., 2011 [ | 34 | - | - | - | sig ↑ | sig ↑ | sig ↑ | sig ↑ | - |
| Berzosa er al., 2011 [ | 34 | - | - | - | sig ↑ | sig ↑ | sig ↑ | sig ↑ | - |
| Bogdanis et al., 2013 [ | 8 | - | sig ↑ | - | sig ↑ | sig ↑ | - | ns ↑ | - |
| Bogdanis et al., 2013 [ | 8 | - | sig ↑ | - | ns ↑ | sig ↑ | - | ns ↑ | - |
| Bouzid et al., 2014 [ | 15 | ns ↑ * | - | - | - | - | sig ↑ * | sig ↑ | - |
| Bouzid et al., 2014 [ | 15 | sig ↑ * | - | - | - | - | ns ↑ * | ns ↑ | - |
| Djordjevic et al., 2012 [ | 58 | - | ns ↑ | - | - | sig ↓ | ns ↓ | - | ns ↑ |
| Djordjevic et al., 2012 [ | 37 | - | sig ↓ | - | - | ns | ns ↑ | - | ns ↑ |
| Falone et al., 2010 [ | 33 | ns ↓ * | - | - | ns * | - | - | - | - |
| Falone et al., 2010 [ | 25 | ns ↑ * | - | - | sig ↓ * | - | - | - | - |
| Finkler et al., 2016 [ | 32 | - | sig ↑ | - | - | sig ↑ | - | ns ↑ | - |
| Fisher et al., 2011 [ | 8 | sig ↑ | sig ↑ | - | - | sig ↑ | sig ↑ | sig ↑ | - |
| Fisher et al., 2011 [ | 8 | sig ↑ | sig ↑ | - | - | sig ↑ | sig ↑ | ns ↑ | - |
| Fisher et al., 2011 [ | 8 | ns ↑ | ns ↑ | - | - | ns ↑ | sig ↑ | sig ↑ | - |
| Groussard et al., 2003 [ | 8 | ns ↓ | ns ↓ | - | - | - | sig ↓ | ns | - |
| Hajizadeh et al., 2017 [ | 62 | - | - | - | - | - | - | - | - |
| Hajizadeh et al., 2017 [ | 65 | - | - | - | - | - | - | - | - |
| Jammes et al., 2004 [ | 19 | - | ns ↑ | - | - | - | - | - | ns ↓ |
| Jamurtas et al., 2018 [ | 12 | - | ns ↑ | - | sig ↑ * | ns ↑ | - | - | - |
| Jamurtas et al., 2018 [ | 12 | - | ns ↑ | - | sig ↑ * | ns ↑ | - | - | - |
| Kyparos et al., 2007 [ | 11 | - | sig ↑ | - | sig ↑ | sig ↑ | - | - | sig ↓ |
| Miyazaki et al., 2001 [ | 9 | - | sig ↑ * | - | - | ns | ns ↑ | ns ↑ | - |
| Miyazaki et al., 2001 [ | 9 | - | sig ↑ * | - | - | ns | ns ↑ | ns ↓ | - |
| Parker et al., 2014 [ | 14 | - | - | ns ↑ | sig ↑ * | - | - | - | - |
| Parker et al., 2014 [ | 14 | - | - | ns ↑ | sig ↑ | - | - | - | - |
| Parker et al., 2014 [ | 14 | - | - | ns ↑ | sig ↑ * | - | - | - | - |
| Parker et al., 2018 [ | 8 | - | sig ↓ | - | - | ns ↑ | sig ↓ | - | - |
| Parker et al., 2018 [ | 8 | - | sig ↓ | - | - | ns ↑ | sig ↓ | - | - |
| Seifi-Skishahr et al., 2008 [ | 10 | ns ↑ | - | - | - | - | - | - | - |
| Steinberg et al., 2007 [ | 15 | ns ↑ | - | - | - | - | - | - | ns ↓ |
| Wadley et al., 2016 [ | 10 | - | - | - | ns ↓ | - | - | - | - |
| Wadley et al., 2016 [ | 10 | - | - | - | ns ↓ | - | - | - | - |
| Wiecek et al., 2018 [ | 20 | - | - | - | - | ns ↑ | ns ↑ | ns ↓ | - |
Note: CAT, catalase; FFM, fat-free mass; GPX, glutathione peroxidase activity; GSH, glutathione; HICE, high-intensity continuous exercise; HIIE, high-intensity interval exercise; LV-HIIE, low-volume high-intensity interval exercise; MDA, malondialdehyde; ns, not significant; SIE, sprint interval exercise; sig, significant; SOD, superoxide dismutase; TAC, total antioxidant capacity; TBARS, thiobarbituric acid reactive substance; TBM, total body mass; VO2max, maximal oxygen uptake; *, significant difference between groups.
Methodological quality assessment questions.
| Reporting | |
|---|---|
| 1. Is the hypothesis/aim/objective of the study clearly described? | Yes 1/No 0 |
| 2. Are the interventions of interest clearly described? Treatments and placebo (where relevant) that are to be compared should be clearly described. | Yes 1/No 0 |
| 3. Are the characteristics of the subjects included in the study clearly described? | Yes 1/No 0 |
| 4. Are the main findings of the study clearly described? Simple outcome data (including denominators and numerators) should be reported for all major findings so that the reader can check the major analyses and conclusions. | Yes 1/No 0 |
| 5. Have all important adverse events that may be a consequence of the intervention been reported? | Yes 1/No 0 |
| Internal validity—bias | |
| 6. Was an attempt made to blind those measuring the main outcomes of the intervention? | Yes 1/No 0/unable to determine 0 |
| 7. Were the statistical tests used to assess the main outcomes appropriate? | Yes 1/No 0/unable to determine 0 |
| Internal validity—confounding (selection bias) | |
| 8. Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited over the same period of time? | Yes 1/No 0/unable to determine 0 |
| 9. Were study subjects randomized to intervention groups? | Yes 1/No 0/unable to determine 0 |
| Power | |
| 10. Did the study have sufficient power to detect an important effect where the probability value for a difference being due to chance is less than 5%? | Yes 1/No 0/unable to determine 0 |
| Methodological quality assessment questions modified from Downs and Black (1998). | |